SciLeads
Company Profile

NextPoint Therapeutics, Inc - Company Profile

All the intelligence your sales team needs on NextPoint Therapeutics inside of the SciLeads platform.

  • Save hours with instant access to verified company insights.
  • Trust accurate, up-to-date data to guide every outreach.
  • Outpace your competitors by engaging leads first.
NextPoint Therapeutics logo

NextPoint Therapeutics Overview

NextPoint Therapeutics is a clinical-stage biotechnology company pioneering precision immuno-oncology through its work on the novel B7-H7/HHLA2 checkpoint axis. Its pipeline targets cancer patients who do not respond to existing PD-1/PD-L1 inhibitors, advancing first-in-class therapies including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional antibody platform. NextPoint partners closely with leading academic and clinical institutions to translate breakthrough science into transformative cancer treatments.

Company Headquarters
Cambridge, Massachusetts, USA
Address
238 Main Street, Cambridge, MA 02142, USA
Industry
Biotechnology, Immuno-Oncology
Website
nextpointtx.com
Ticker Symbol & Exchange
Private (Series B-funded)
LinkedIn Profile
linkedin.com/company/nextpoint-therapeutics

* Data accurate as of 6/5/2025

NextPoint Therapeutics Industry Data & Analytics

Access detailed insights into NextPoint Therapeutics, including clinical activity, drug development, funding, and market presence. Our data includes up-to-date information on trials, products, leadership, and strategic positioning to support business development and competitive research.

32+

People

Discover key individuals at NextPoint Therapeutics, including job roles, location, and outreach contact information where available.

“SciLeads has been critical to the success of our sales and marketing efforts. I don't know where we would be without its data and insights.”

Paul WrightCommerical Marketing Director

5x

your pipeline

with SciLeads

MetabolonFree Trial

Become better at selling to scientists,
join today.